Boardroom Alpha
Boardroom Alpha
XRAY · Current Report (Form 8-K) · Filed June 4, 2026

Dentsply Sirona Inc — Current Report (Form 8-K)

Form
8-K
Filed
June 4, 2026
Period
Jun 2, 2026
Ticker
XRAY
Accession
0000818479-26-000165
Boardroom Alpha · Filing insights

Twelve directors were elected to serve until the next annual meeting. Deloitte was ratified as auditor, and shareholders approved executive compensation and a 15,000,000-share Omnibus Plan increase.

About Dentsply Sirona Inc
Market cap
$2.2B
1Y TSR
−12.1%
3Y TSR
−30.3%
Board grade
C-
Sector
Healthcare
CEO
Daniel T Scavilla
Last annual meeting: Jun 2, 2026 · View full Dentsply Sirona Inc profile →
xray-20260602

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K
CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

June 2, 2026
Date of Report (Date of earliest event reported)

DENTSPLY SIRONA Inc.
(Exact name of registrant as specified in its charter)
Delaware
0-16211
39-1434669
(State or other jurisdiction of incorporation or organization)
(Commission File Number)
(I.R.S. Employer Identification No.)
13320 Ballantyne Corporate Place,
Charlotte
North Carolina
28277-3607
(Address of Principal Executive Offices)
(Zip Code)
(844) 848-0137
(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, par value $0.01 per shareXRAYThe Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
o





Item 5.07 Submission of Matters to a Vote of Security Holders

The annual meeting of stockholders (the “Annual Meeting”) of DENTSPLY SIRONA Inc. (the “Company”) was held on June 2, 2026. The following matters were voted upon at the Annual Meeting, with the results indicated:

1.Election of twelve directors to serve until the next annual meeting of stockholders or until their respective successors are duly elected and qualified.
Director
For
Against
Abstain
Broker Non-Votes
1a.
Michael J. Barber167,115,711642,65182,95314,762,922
1b.
James D. Forbes167,030,832726,83183,65214,762,922
1c.
Brian T. Gladden167,131,075633,35876,88214,762,922
1d.
Betsy D. Holden144,275,61923,407,281158,41514,762,922
1e.
Clyde R. Hosein166,571,4261,166,383103,50614,762,922
1f.
Gregory T. Lucier164,966,2222,723,724151,36914,762,922
1g.
Jonathan J. Mazelsky164,501,6883,177,506162,12114,762,922
1h.
Brian P. McKeon167,101,344657,81382,15814,762,922
1i.
Daniel T. Scavilla167,087,998674,88478,43314,762,922
1j.
Leslie F. Varon166,054,8181,611,470175,02714,762,922
1k.Janet S. Vergis165,269,8252,490,76980,72114,762,922
1l.Donald J. Zurbay116,568,82151,059,271213,22314,762,922

2.Ratification of appointment of Deloitte and Touche LLP as the Company’s independent registered public accountants for 2026.
For
Against
Abstain
Broker Non-Votes
182,033,381465,064105,792

3.Approval, by non-binding advisory vote, of the Company’s executive compensation for 2025.
For
Against
Abstain
Broker Non-Votes
158,496,0589,090,084255,17314,762,922
4.Approval of Amendment No. 2 to the Company’s 2024 Omnibus Incentive Plan (the “2024 Plan”) to increase the number of shares of the Company’s Common Stock issuable under the 2024 Plan by 15,000,000 shares.
For
Against
Abstain
Broker Non-Votes
139,933,38827,713,777194,15014,762,922



SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

DENTSPLY SIRONA Inc.

By:
/s/ Daniel T. Scavilla
Daniel T. Scavilla
President and Chief Executive Officer

Date: June 4, 2026

From this filing to the file

Every SEC filing, parsed structured.

Boardroom Alpha indexes every 8-K, 10-K, 10-Q, and proxy back to 2000 — vote tabulations, comp tables, red flags, insider transactions, all queryable the day they hit EDGAR.

Independent — issuer-pays-free, ideology-free, U.S.-owned.

More filings

Other filings from Dentsply Sirona Inc (XRAY)

Reference

Frequently asked questions

When did Dentsply Sirona Inc file this 8-K?
Dentsply Sirona Inc (XRAY) filed this Current Report (Form 8-K) with the SEC on June 4, 2026. The accession number assigned by EDGAR is 0000818479-26-000165.
What does an 8-K disclose?
Form 8-K is the SEC's current-report form, used to disclose material events between periodic reports (10-K / 10-Q). Triggers include CEO/CFO departures, acquisitions, bankruptcies, earnings releases, auditor changes, changes in fiscal year, and amendments to corporate governance. Each 8-K is keyed to one or more Item numbers (1.01 through 9.01).
What is the key takeaway from this filing?
Twelve directors were elected to serve until the next annual meeting. Deloitte was ratified as auditor, and shareholders approved executive compensation and a 15,000,000-share Omnibus Plan increase. This is Boardroom Alpha's one-line summary of the current report; see the full filing text above for the formal disclosure.
What Item codes does an 8-K cover?
An 8-K's Item codes (1.01 through 9.01) specify what kind of event is being disclosed — e.g. Item 1.01 for entering a material agreement, Item 5.02 for departure/election of directors and executive officers, Item 8.01 for other events. The Item codes for this 8-K appear in the filing text above.
Where can I find Dentsply Sirona Inc's prior current reports on EDGAR?
The SEC EDGAR browser lists every 8-K Dentsply Sirona Inc has filed under CIK 818479, sortable by date. Use the "View on SEC EDGAR" link in the page header, or browse directly via https://www.sec.gov/cgi-bin/browse-edgar.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer